Burden of cervical, anal, and oral HPV in an inner-city pre-vaccine adolescent population

Journal of Urban Health

Volumn 90, Issue 1, 2013, Pages 141-146

  Schlecht, Nicolas F ^a   Rojas, Mary ^b   Lorde Rollins, Elizabeth ^c   Nucci Sack, Anne ^c   Strickler, Howard D ^a   Burk, Robert D ^a   Diaz, Angela ^c  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b MAIMONIDES MEDICAL CENTER   (United States)

^c Mount Sinai Adolescent Health Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

WART VIRUS VACCINE;

ADOLESCENT; ADULT; ANUS TUMOR; ARTICLE; FEMALE; HUMAN; MALE; PAPILLOMAVIRUS INFECTION; PREVALENCE; STATISTICS; UNITED STATES; URBAN POPULATION; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX TUMOR; VIROLOGY;

ADOLESCENT; ADULT; ANUS NEOPLASMS; CERVICAL INTRAEPITHELIAL NEOPLASIA; FEMALE; HUMANS; MALE; NEW YORK CITY; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; PREVALENCE; URBAN POPULATION; UTERINE CERVICAL NEOPLASMS; YOUNG ADULT;

MLCS; MLOWN;

EID: 84878480574     PISSN: 10993460     EISSN: 14682869     Source Type: Journal    
DOI: 10.1007/s11524-012-9756-9     Document Type: Article

References (19)

1. FUTURE II. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med. 2007; 356(19): 1915-1927.
2. Clifford GM, Gallus S, Herrero R, et al. Worldwide distribution of human papillomavirus types in cytologically normal women in the International Agency for Research on Cancer HPV prevalence surveys: a pooled analysis. Lancet. 2005; 366(9490): 991-998.
3. Olsson SE, Kjaer SK, Sigurdsson K, et al. Evaluation of quadrivalent HPV 6/11/16/18 vaccine efficacy against cervical and anogenital disease in subjects with serological evidence of prior vaccine type HPV infection. Hum vaccines. 2009; 5(10): 696-704.
4. Centers for Disease Control and Prevention. National and state vaccination coverage among adolescents aged 13 through 17 years - United States, 2010. MMWR Morb Mortal Wkly Rep. 2011; 60(33): 1117-1123.
5. Castle PE, Schiffman M, Gravitt PE, et al. Comparisons of HPV DNA detection by MY09/11 PCR methods. J Med Virol. 2002; 68(3): 417-423.
6. Bouvard V, Baan R, Straif K, et al. A review of human carcinogens?Part B: biological agents. Lancet Oncol. 2009; 10(4): 321-322.
7. Burk RD, Chen Z, Harari A, et al. Classification and nomenclature system for human Alphapapillomavirus variants: general features, nucleotide landmarks and assignment of HPV6 and HPV11 isolates to variant lineages. Acta derm venereol Alpina Panonica et Adriatica. 2011; 20(3): 113-123.
8. Fleiss JL. The design and analysis of clinical experiments. New York: Wiley; 1986.
9. Villa L, Ault K, Giuliano A, et al. Immunologic responses following administration of a vaccine targeting human papillomavirus types 6, 11, 16, and 18. Vaccine. 2006; 24(27-28): 5571-5583.
10. Haupt RM, Wheeler CM, Brown DR, et al. Impact of an HPV6/11/16/18 L1 virus-like particle vaccine on progression to cervical intraepithelial neoplasia in seropositive women with HPV16/18 infection. Int J Cancer. 2011; 129(11): 2632-2642.
11. Garland SM, Hernandez-Avila M, Wheeler CM, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med. 2007; 356(19): 1928-1943.
12. Kemp TJ, Hildesheim A, Safaeian M, et al. HPV16/18 L1 VLP vaccine induces cross-neutralizing antibodies that may mediate cross-protection. Vaccine. 2011; 29(11): 2011-2014.
13. Wheeler CM, Castellsague X, Garland SM, et al. Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol. 2012; 13(1): 100-110.
14. Gillison ML, Broutian T, Pickard RK, et al. Prevalence of oral HPV infection in the United States, 2009-2010. JAMA. 2012; 307(7): 693-703.
15. Chaturvedi AK, Engels EA, Anderson WF, Gillison ML. Incidence trends for human papillomavirus-related and -unrelated oral squamous cell carcinomas in the United States. J Clin Oncol Off J Am Soc Clin Oncol. 2008; 26(4): 612-619.
16. Hoots BE, Palefsky JM, Pimenta JM, Smith JS. Human papillomavirus type distribution in anal cancer and anal intraepithelial lesions. Int J Cancer. 2009; 124(10): 2375-2383.
17. Nielsen A, Munk C, Kjaer SK. Trends in incidence of anal cancer and high-grade anal intraepithelial neoplasia in Denmark, 1978-2008. Int J Cancer. 2012; 130(5): 1168-1173.
18. Palefsky JM, Giuliano AR, Goldstone S, et al. HPV vaccine against anal HPV infection and anal intraepithelial neoplasia. N Engl J Med. 2011; 365(17): 1576-1585.
19. Kreimer AR, Gonzalez P, Katki HA, et al. Efficacy of a bivalent HPV 16/18 vaccine against anal HPV 16/18 infection among young women: a nested analysis within the Costa Rica Vaccine Trial. Lancet Oncol. 2011; 12(9): 862-870.